The Quick-Tissue™ Series is a revolutionary new way to generate human cells, tissues, and organs.
These potent cocktails of transcription factors (TFs) transform your stem cells of choice into high-quality tissues in a scalable, speedy manner.
Efficient delivery of TFs to cells is achieved in two different ways: Synthetic mRNAs or Sendai Virus vectors.
Speedy and Simple
The Quick-Tissue™ Series is a complete reagent set that performs the fastest differentiation of induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs).
For example, Elixirgen Scientific’s Quick-Neuron™ Cholinergic kit performs faster than any of the protocols used by researchers and other companies today. ESCs/iPSCs become functionally mature neurons in only one week. Such speed does not come at the cost of efficiency – past data shows that up to 90% of iPSCs and ESCs differentiate into cholinergic neurons.
The The Quick-Tissue™ Series employs simple and easy steps to differentiate cells. There are only 4 treatments for the RNA-based kits and only 1 treatment for Sendai Virus vector-based kits.
The The Quick-Tissue™ Series offers consistent and reproducible cell differentiation. For example, the timing of differentiation, experiment-to-experiment, and well-to-well variation are tightly controlled. These are desirable features, especially for the high throughput screening (HTS) of drugs and for testing the toxicity of chemicals for safety.
Elixirgen Scientific’s Quick-Neuron™ cells fire strong and unique synchronized bursts when they are measured using multielectrode array (MEA; see below). Robust compound-specific dose responses were observed on MEA using our mixed neuron product. A wide variety of neurons derived from healthy individuals as well as disease patients are available.
Phase contrast image of Mixed Neurons on MEA (day 50 post-thaw)
Multiple subtype-specific markers were examined by immunocytochemistry
Use Any Cells
With the Quick-Tissue™ kits, researchers can use cells of their choice and differentiate them into specific cell types. For example, researchers can use human ES cells and human iPS cells from a variety of sources or cells that they have generated by themselves. In addition, a large number of human iPS cells derived from patients with many different kinds of diseases are becoming available from the California Institute for Regenerative Medicine through the Coriell Biorepository. It has also become popular to make specific mutations in human ES and iPS cells by using genome editing technologies such as CRISPR/Cas9. Researchers can use any of these human ES and iPS cells and differentiate them to specific cell types for their own studies.
Diseases on your choice
The California Institute for Regenerative Medicine (CIRM) has granted a license to Elixirgen Scientific to commercially distribute differentiated tissues derived from CIRM’s patient iPS cell lines. If you are interested in neurons derived from particular disease-associated or multiple control iPS cell lines, please contact us.
The CIRM iPSC repository includes over 1,500 iPSC lines, encompasses 5 different disease classes, and contains age-matched controls for each disease patient iPSC line. Further details such as demographic and clinical data about the collection can be found at here.
|Category||No. of iPSC lines|
|Control Cell Lines||302|
|Autism Spectrum Disorder||113|
|Blinding Eye Diseases||175|
|Age-related Macular Degeneration||120|
|Glaucoma, Primary Open Angle||21|
|Cardiomyopathy, Left Ventricular Non-Compaction||9|
|Cardiomyopathy, Arrhythmogenic Right Ventricular||2|
|NASH and Steatosis||38|
|Idiopathic Pulmonary Fibrosis||191|
Genome-corrected iPS cells
Differentiated skeletal muscle cells from genome-corrected iPS cells (B,D) show loss of disease specific RNA foci compared to cells from non-corrected iPS cells (A, C).
Wang et al., (2018). Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9. Molecular Therapy 2018;26:2617. [PubMed] [Molecular Therapy] [Kindly provided by Dr. Xia, University of New Mexico]
The The Quick-Tissue™ Series reagents are composed of cocktails of transcription factors, and thus, they are available in different sizes and scales. Elixirgen Scientific offers small-scale differentiation kits with reagents sufficient to differentiate cells in 4 wells of 24-well microtiter plate. For toxicity screening, Elixirgen Scientific offers a medium size differentiation kit sufficient to differentiate cells in 1x 96-well microtiter plates. For drug screening and other large-scale screening purposes, Elixirgen Scientific offers larger sizes differentiation kits sufficient to differentiate cells in 100x 96-well microtiter plates.
Thanks to its basis in RNA technology or Sendai Virus technology, the The Quick-Tissue™ Series treatment does not leave behind a genetic footprint in the cells it differentiates, unlike many common differentiation strategies. This ensures that your experiments with subjects such as disease iPSCs will not be unduly modified during the differentiation process.
Quick-Tissue™ Series Kits with RNA
The The Quick-Tissue™ Series kits not marked as “SeV” use advanced RNA technology in order to differentiate your cells without a trace. Since RNA is transcribed in the cytoplasm then used up, there will not be gene expression beyond what is required, and the kit’s RNA will be consumed in order to enact the differentiation.
Quick-Tissue™ Series Kits with Sendai Virus
The The Quick-Tissue™ Series SeV kits partially rely on the Sendai Virus (SeV) to cause differentiation for its subject cells. SeV is a RNA-virus – none of the phases of its life cycle involve DNA, so there is little risk of genomic integration. In addition, the particular type of SeV used by Elixirgen Scientific’s kits is temperature sensitive; it is most active at 33 degrees C, then becomes neutralized once its temperature reaches 37 degrees C. This neutralization successfully eliminates the virus from the cells.
Pharmaceutical companies and researchers can use the Quick-Tissue™ Series’ kits for drug screening. Our kits are best suited to the high throughput screening (HTS) with robots and robotic platforms.
Differentiated cells produced by the Quick-Tissue™ Series kits could be used quickly and effectively for toxicity screening of industrial and environmental substances.
“Precision Medicine” can help select the most suitable drugs for individual patients (“personalized or tailored medicine”). Our kits enable these goals through differentiating patient-specific iPS cells.
“Tissue Chips or organs-on-chips” can eventually be used for testing safety and efficacy of drug candidates before any testing in humans. Our kits can significantly accelerate these processes.
The Quick-Tissue™ Series’ kits can be used to differentiate stem cells on top of 3-D printed scaffolds – currently one of the most common methods for such printing.
One key paradigm in Regenerative Medicine is to differentiate human ES and iPS cells into desired cell types and transplant them to patients in need of these cells/tissue/organs.
Researchers have traditionally used non-human cells for basic and applied biomedical research. The Quick-Tissue™ series increases the availability of human differentiated cells in biomedical research.
Lower Barrier of Entry
The simplicity and cost of the Quick-Tissue™ Series ensures that even novice scientists can conduct advanced stem cell research.
Stop waiting months for tissues!
Elixirgen Scientific provides pluripotent stem cell differentiation services with the world’s fastest turnaround time. Customers can simply ship live iPS/ES cells in a T-25 flask and will receive differentiating or terminally differentiated cells in a week (express service) or two weeks (regular service).
Currently Elixirgen Scientific offers cholinergic neuron, dopaminergic neuron, and skeletal muscle cell differentiation services. More tissue types are coming soon!